Colcrys is an alkaloid indicated for prophylaxis and treatment of acute gout flares in ages >16 years and for the treatment of Familial Mediterranean Fever (FMF) in children ages ≥4 and adults. It is thought to interfere with the intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediates activation of interleukin-1b. Also, it is thought to inhibit beta-tubulin polymerization into microtubules, which prevents the activation, degranulation, and migration of neutrophils thought to mediate some gout symptoms.
In 2010, the Food and Drug Administration (FDA) mandated that companies cease production of single-ingredient oral colchicine products, with the exception of Colcrys. Many single ingredient oral colchicine products had been used by the medical community for decades but had not received the mandatory modern-day FDA-approval required of all prescription drugs. Colcrys received FDA approval in 2009.
Colchine Tablets will be available as a 0.6mg strength in U.S. pharmacies beginning later this week.